Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence
NCT01707758 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2013-05-16
Summary
The primary objective is to develop a rapid in vitro screening assay for detection of pancreatic cancer biomarkers in blood of patients with pancreatic cancer.
Conditions
Sponsors & Collaborators
-
University of Kansas
lead OTHER
Principal Investigators
-
Stephen Williamson, MD · University of Kansas Medical Center Cancer Center
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2012-10-31
- Primary Completion
- 2013-02-28
- Completion
- 2013-02-28
More Related Trials
-
Optical and Biochemical Biomarkers in Early Pancreatic Cancer
NCT03404661 ·Status: COMPLETED
-
Studying Biomarkers in Patients With Pancreatic Cancer
NCT00900003 ·Status: COMPLETED
-
Characterizing the Pancreatic Cancer Proteome From Pancreatic Juice
NCT02277834 ·Status: COMPLETED
-
Characterization of Mechanical Tissue Properties in Patients With Pancreatic, Liver, or Colon Cancer
NCT03137706 ·Status: TERMINATED
-
Nutrition Support to Improve Outcomes in Patients With Unresectable Pancreatic Cancer
NCT02681601 ·Status: TERMINATED ·Phase: NA
-
Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma
NCT03077685 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma
NCT03334708 ·Status: RECRUITING
-
ALateral Flow Assay to Detect QSOX1 Peptide in Patients With or at Risk for Pancreatic Cancer
NCT04064034 ·Status: COMPLETED ·Phase: NA
-
RNA Precision Oncology in Advanced Pancreatic Cancer
NCT04476537 ·Status: TERMINATED ·Phase: NA
-
Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment
NCT06574620 ·Status: RECRUITING ·Phase: NA
-
Biomarkers in Plasma Specimens From Patients Treated on Study CALGB-80303
NCT01664169 ·Status: COMPLETED
-
Pancreatic Cancer Initial Detection Via Liquid Biopsy
NCT06283576 ·Status: ENROLLING_BY_INVITATION
-
Minimally Invasive Detection of Lymphatic Micrometastases in Pancreatic Cancer
NCT00826982 ·Status: COMPLETED
-
The Role of Muscle Cachexia in Pancreatic Cancer
NCT02515513 ·Status: WITHDRAWN ·Phase: NA
-
First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer
NCT04665947 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
NCT01783171 ·Status: COMPLETED ·Phase: PHASE1
-
Identification of Biomarkers Associated With the Presence of Malignant Pancreatic Lesions Compared to Benign Lesions.
NCT06397846 ·Status: RECRUITING ·Phase: NA
-
Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer
NCT00429858 ·Status: TERMINATED ·Phase: PHASE2
-
Multi-omics Model for Pancreatic Cancer Screening Using cfDNA
NCT06456281 ·Status: RECRUITING
-
Verification of Predictive Biomarkers for Pancreatic Cancer Treatment Using Multicenter Liquid Biopsy
NCT04241367 ·Status: COMPLETED
-
ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer
NCT00056537 ·Status: COMPLETED ·Phase: PHASE1
-
Olaparib in Treating Patients With Stage IV Pancreatic Cancer
NCT02677038 ·Status: COMPLETED ·Phase: PHASE2
-
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
NCT06122896 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma.
NCT02072616 ·Status: TERMINATED ·Phase: NA
-
Tissue Pharmacokinetics of Intraoperative Gemcitabine in Resectable Adenocarcinoma of the Pancreas
NCT01276613 ·Status: TERMINATED ·Phase: EARLY_PHASE1